As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, Novem ...

More than 400 million people currently suffer from some type of diabetes, a figure that represents 1 in 11 adults worldwide ...

Patients with moderate to severe HS experienced sustained symptomatic and quality-of-life improvements with the monoclonal ...

Autism spectrum disorder diagnoses increased 175% from 2011 to 2022, and is becoming more prevalent in young adults. (JAMA ...

AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.

In May 2024, Novartis announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective ...

Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...

He explained that for about eight years in the 80s, he sold mammography equipment, so when he noticed discharge from his ...

Last year, AstraZeneca reported that a new drug to treat Wilson disease developed by its Alexion ... with current treatment – including skin rash and blisters, vomiting and diarrhoea, and ...

As we head towards Lung Cancer Awareness Month in November disease healthcare ... Merck, AstraZeneca, Amgen, Johnson & Johnson, Daiichi Sankyo and Genentech. Each one has skin in the game when ...